Collaboration, License, and Other Agreements - Alnylam Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2019
Disaggregation of Revenue [Line Items]
Revenues	$ 3,362.7	$ 2,936.2	$ 9,682.9	$ 8,758.5
Alnylam Pharmaceuticals, Inc. Collaboration Agreement
Disaggregation of Revenue [Line Items]
Upfront payment made					$ 400.0
Collaborative arrangement additional payment eligible			$ 100.0
Alnylam Pharmaceuticals, Inc. Collaboration Agreement | Clinical Proof-of-Principle Milestone | Alnylam
Disaggregation of Revenue [Line Items]
Revenues	$ 100.0
Alnylam Pharmaceuticals, Inc. Collaboration Agreement | Alnylam Pharmaceuticals, Inc. Stock Purchase Agreement
Disaggregation of Revenue [Line Items]
Cash consideration for Stock Purchase Agreement					$ 400.0